Search

Displaying results 2091 - 2100 of 10000 in total
  1. Drug

    Givosiran

    go.drugbank.com/drugs/DB15066
    Approved

    [L10202] It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a genetic disorder … [L10202] Givosiran represents an important step forward in the treatment of acute hepatic porphyria as it is the first approved pharmacotherapy for the prevention of acute attacks - previous strategies

  2. Drug

    Ethambutol

    go.drugbank.com/drugs/DB00330
    ApprovedInvestigational

    [A229048] Ethambutol was granted FDA approval on 6 November 1967.[L31663] … [L31743] Ethambutol was first described in the literature in 1961.[A229048] It was developed out of a need for therapies active against isoniazid resistant strains of _Mycobacterium tuberculosis_.

    Synonyms: (+)-N,N'-bis(1-(hydroxymethyl)propyl)ethylenediamineProducts: E-BUTOL TABLET 400 mg
  3. Drug

    Ravulizumab

    go.drugbank.com/drugs/DB11580
    ApprovedInvestigational

    [A244465] Ravulizumab was first approved by the FDA on December 21, 2018, for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome in children and adults. … It is a humanized monoclonal IgG2/4 kappa antibody produced in Chinese hamster ovary (CHO) cells.

  4. Drug

    Eladocagene exuparvovec

    go.drugbank.com/drugs/DB16780
    ApprovedInvestigational

    [L43642] Eladocagene exuparvovec received EMA approval in July 2022. … [A253687] It was subsequently approved by the FDA in November 2024.[L51898,L51893]

  5. Drug

    Eculizumab

    go.drugbank.com/drugs/DB01257
    ApprovedInvestigational

    [L6919,A2245,A2246] Eculizumab was granted FDA approval on 16 March 2007. … [L6919] In Q1 2023, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion of two formulations of eculizumab indicated for the treatment of paroxysmal nocturnal hemoglobinuria

  6. Drug

    Sertaconazole

    go.drugbank.com/drugs/DB01153
    Approved

    Sertaconazole nitrate is an antifungal medication of the imidazole class. It is available in topical formulations for the treatment of skin infections such as athlete's foot.

  7. Drug

    Alfacalcidol

    go.drugbank.com/drugs/DB01436
    ApprovedInvestigationalNutraceutical

    [A234044] It plays an essential function in calcium homeostasis and bone metabolism. … Alfacaldisol is activated by the enzyme 25-hydroxylase in the liver to mediate its effects in the body, or most importantly, the kidneys and bones.

  8. Drug

    Vorinostat

    go.drugbank.com/drugs/DB02546
    ApprovedInvestigational

    It is the first in a new class of agents known as histone deacetylase inhibitors. … A recent study suggested that vorinostat also possesses some activity against recurrent glioblastoma multiforme, resulting in a median overall survival of 5.7 months (compared to 4 - 4.4 months in earlier

  9. Drug

    Cangrelor

    go.drugbank.com/drugs/DB06441
    ApprovedInvestigational

    Cangrelor was approved by the FDA in June 2015 for intravenous application. … An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an active drug not requiring metabolic conversion therefore providing a rapid onset

  10. Drug

    Acetohydroxamic acid

    go.drugbank.com/drugs/DB00551
    ApprovedInvestigational

    Acetohydroxamic Acid, a synthetic drug derived from hydroxylamine and ethyl acetate, is similar in structure to urea. In the urine, it acts as an antagonist of the bacterial enzyme urease. … It is used, in addition to antibiotics or medical procedures, to treat chronic urea-splitting urinary infections.

    Synonyms: N-Hydroxyacetamide, N-Acetylhydroxylamine